Romosozumab

Romosozumab has been studied in 74 papers since 2020: 4 trials and 18 observational studies in people, 4 in animals, 46 reviews; 44 in the past year. It is an approved medicine. The newest paper, Nov 13, 2026: “Should romosozumab be used in patients with a history or risk of CVD?”.

InterventionApproved 2019

74 papers study it61 findingsUpdated

MeSH

8 new papers in 30 daysSee all 70 papers on romosozumab

At a glance

Romosozumab increases spine bone density in a human trial; independent labs link it with higher bone density and lower mortality in osteoporosis. Cardiovascular associations point both ways, including higher stroke risk with prior cardiovascular history. Most trials for non-aging uses are sponsored by Amgen and UCB Biopharma; a trial ended over a year ago without posted results.

61 findings in 29 papers from 2020 to 2026, 15 of them since April 2026

Independent labs found the same change in people. 18 independent labs in 6 countries; 35 trials, none about aging, 1 with no results posted.

“they did not differ significantly between the romosozumab and placebo groups over weeks 6 to 20 (p = 0.198)”
A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip FracturesThe Journal of bone and joint surgery. American volume2020doi:10.2106/jbjs.19.00790

2 of its findings point the other way.

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
  • 18 independent labs in 6 countries
  • 2 findings against
  • 35 trials, none about aging, 1 with no results posted
  • Funders: Amgen and others
  • 3 of 43 findings with company ties
  • 23 of 35 trials sponsored by its developers
  • Human trial4
  • Humans15
  • Animals4

Studies in people

2 studies gave romosozumab to people and measured what changed.

What changedDesignPeopleSource

up: Increases lumbar spine bone mineral density+13.7% vs. +8.5%

no change: Has no effect on knee osteophyte development

Randomized trial12 months112 peoplewomenmean age 80.9 yearsElderly women aged 75–90 years with primary osteoporosis and knee osteoarthritisScientific reports, Jul 1, 2025

no change: Has no effect on timed Up and Go testp = 0.198

no change: Has no effect on time to radiographic fracture healing16.4 to 16.9 weeks across treatment groups

no change: Has no effect on Radiographic Union Scale for Hip

Randomized trialweeks 6 to 20332 people55 to 94 yearsOlder adults; open reduction and internal fixation of intertrochanteric or femoral neck hip fracturesThe Journal of bone and joint surgery. American volume, Jan 22, 2020

What did studies of romosozumab find?

34

Studies of romosozumab measured 34 outcomes; the most studied are mortality (4 studies), bone fracture (2) and bone mineral density (2).

Mortality

downin humans4HR 0.554–0.68

4 studies
  1. Romosozumab is linked with lower mortality in humans (compared with teriparatide/abaloparatide in osteoporosis).

    “Romosozumab participants continued to demonstrate a significantly lower hazard (and improved survival probabilities) of myocardial infarction, heart failure, and death”

    Humanscompared with teriparatide/abaloparatide in osteoporosis1 year

    Cardiovascular Outcomes Following Therapeutic Sclerostin Inhibition Compared With Alternative Anabolic Therapies: A Real-World Propensity Score-Matched Analysis

    Journal of osteoporosis

  2. Romosozumab is linked with lower mortality in humans (without a prior cardiovascular history) (HR 0.554, 95% CI 0.316-0.972).

    “lower mortality at 3-year (HR 0.554, 95% CI 0.316-0.972, p = 0.038) and 5-year follow-up (HR 0.533, 95% CI 0.312-0.913, p = 0.028)”

    Humanswithout a prior cardiovascular history3 years

    Romosozumab linked to lower risk without prior cardiovascular disease

    Therapeutic advances in musculoskeletal disease

  3. Romosozumab is linked with lower mortality in humans (chronic kidney disease) (6.6% vs. 9.5%; RR, 0.693 [95% CI, 0.526-0.913]).

    “all-cause mortality (6.6% vs. 9.5%; RR, 0.693 [95% CI, 0.526-0.913])”

    Humanschronic kidney disease1095 days94.9% and 93.8% womens

    Cardiovascular Outcomes Associated with Romosozumab Versus Denosumab in Chronic Kidney Disease

    Medicina (Kaunas, Lithuania)

  4. Romosozumab is linked with lower mortality in humans (compared to teriparatide in osteoporosis) (HR 0.68, 95% CI 0.49-0.94).

    “romosozumab was associated with significantly lower all-cause mortality compared to teriparatide (hazard ratio [HR] 0.68, 95% CI 0.49-0.94).”

    Humanscompared to teriparatide in osteoporosisn = 2,470

    Romosozumab versus teriparatide and risk of all-cause mortality in patients with osteoporosis: a real-world propensity score-matched cohort study

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Bone fracture

downin humans2

2 studies
  1. Romosozumab protects against bone fracture in humans.

    “Romosozumab offers substantial fracture protection”

    Review

    Should romosozumab be used in patients with a history or risk of CVD?

    European journal of endocrinology

  2. Romosozumab prevents bone fracture in humans (followed by an anti-resorptive).

    “Romosozumab is given as monthly s.c. injections for 1 year, followed by an anti-resorptive. This sequence prevents more fractures than anti-resorptive therapy alone.”

    Reviewfollowed by an anti-resorptive1 year

    EXTENSIVE EXPERTISE IN ENDOCRINOLOGY: Osteoporosis management

    European journal of endocrinology

More on Bone fracture

Bone mineral density

upin humans2+3.7%

2 studies
  1. Romosozumab is linked with higher bone mineral density in humans (postmenopausal women) (+ 3.7%).

    “After six months of RMZ, BMD significantly increased at both TH (+ 3.7%; 0.718 ± 0.103 g/cm2 vs. 0.698 ± 0.116 g/cm2; p < 0.01) and FN”

    Humanspostmenopausal womenhip6 monthsfemalesn = 74

    Very short-term monitoring of Romosozumab longitudinal effects in a cohort of postmenopausal women by means of Radiofrequency Echographic Multi-Spectrometry (REMS) technology

    Aging clinical and experimental research

  2. Romosozumab increases bone mineral density in humans (Postmenopausal women at high fracture risk; compared with antiresorptive agents).

    “Compared to antiresorptive agents, its unique mechanism of action results in a quicker and greater increase in bone mineral density”

    ReviewPostmenopausal women at high fracture risk; compared with antiresorptive agentsbonefemales

    Romosozumab for the treatment of postmenopausal women at high risk of fracture

    Expert opinion on biological therapy

More on Bone mineral density

Lumbar spine bone mineral density

upin humans1

1 study
  1. Romosozumab increases lumbar spine bone mineral density in humans (versus denosumab) (+13.7% vs. +8.5%).

    “The primary outcome of the study was the percentage change in LS-BMD at 12 months, which was significantly greater in the romosozumab group (13.7% [10.8–16.7]) than in the denosumab group (8.5% [6.5–10.5]; p = 0.0035) (Fig. (a)).”

    Human trialversus denosumab12 monthsfemalesn = 112

    A randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis

    Scientific reports

  2. Romosozumab increases lumbar spine bone mineral density in humans (primary osteoporosis and knee osteoarthritis) (13.7% vs 8.5%, p = 0.0035).

    “The mean percentage change in LS-BMD at 12 months was significantly higher in the romosozumab group (13.7%) than in the denosumab group (8.5%; p = 0.0035).”

    Human trialprimary osteoporosis and knee osteoarthritislumbar spine12 monthsfemales

    A randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis

    Scientific reports

More on Lumbar spine bone mineral density

Antidiabetic medication initiation

no changein humans1HR 1.15

1 study
  1. Romosozumab was not clearly linked with antidiabetic medication initiation in humans (Patients with osteoporosis and no prior diabetes; compared with denosumab) (HR 1.15, 95% CI 0.95–1.40).

    “Similarly, no significant differences were observed for broader diabetes diagnoses (HR, 1.01; 95% CI, 0.86–1.20), antidiabetic medication initiation (HR, 1.15; 95% CI, 0.95–1.40)”

    HumansPatients with osteoporosis and no prior diabetes; compared with denosumabn = 6,581

    Diabetes risk did not clearly differ between osteoporosis drugs

    Diabetes & metabolism

Incident type 2 diabetes

no changein humans1HR 0.93

1 study
  1. Romosozumab was not clearly linked with incident type 2 diabetes in humans (Patients with osteoporosis and no prior diabetes; compared with denosumab) (HR 0.93, 95% CI 0.78–1.12; log-rank p = 0.468).

    “Romosozumab initiation was not associated with a significant difference in incident T2D compared with denosumab”

    HumansPatients with osteoporosis and no prior diabetes; compared with denosumabn = 6,581

    Diabetes risk did not clearly differ between osteoporosis drugs

    Diabetes & metabolism

More on Incident type 2 diabetes

Alveolar bone mineral density

upin humans1

1 study
  1. Romosozumab is linked with higher alveolar bone mineral density in humans (osteoporosis).

    “During sequential bone-anabolic therapy, al-BMD significantly increased over time, eventually reaching levels comparable to those of elderly non-osteoporotic controls.”

    Humansosteoporosisfemales

    Alveolar Bone Mineral Density Correlates with Lumbar Spine Bone Mineral Density During Romosozumab Therapy: A Prospective Observational Study In Osteoporosis

    Research SquarePreprint

More on Alveolar bone mineral density

TRACP-5b

downin humans1

1 study
  1. Romosozumab is linked with lower TRACP-5b in humans (osteoporosis) (-32.1% vs. -33.1%).

    “TRACP-5b - 32.1% vs. - 33.1%, P = 0.746”

    Humansosteoporosissubcutaneous210 mg monthly12 months

    Equivalent Twelve-Month Bone Mineral Density Response to Romosozumab in Patients Aged ≥ 85 Years and < 85 Years: A Multi-center Real-World Cohort Study (n = 417) from Northern Japan

    Calcified tissue international

More on TRACP-5b

P1NP

downin humans1

1 study
  1. Romosozumab is linked with lower P1NP in humans (osteoporosis) (median -16.4% vs. -19.6%).

    “Bone turnover markers decreased similarly in both age strata (P1NP median - 16.4% vs. - 19.6%, P = 0.928”

    Humansosteoporosissubcutaneous210 mg monthly12 months

    Equivalent Twelve-Month Bone Mineral Density Response to Romosozumab in Patients Aged ≥ 85 Years and < 85 Years: A Multi-center Real-World Cohort Study (n = 417) from Northern Japan

    Calcified tissue international

More on P1NP

Lumbar spine bone mineral density

upin humans1

1 study
  1. Romosozumab is linked with higher lumbar spine bone mineral density in humans (osteoporosis) (+10.9% [IQR 6.2 to 20.0]).

    “+ 10.9% [IQR 6.2 to 20.0] in patients aged ≥ 85 years (n = 69) (Mann-Whitney P = 0.926)”

    Humansosteoporosissubcutaneous210 mg monthly12 monthsn = 69

    Equivalent Twelve-Month Bone Mineral Density Response to Romosozumab in Patients Aged ≥ 85 Years and < 85 Years: A Multi-center Real-World Cohort Study (n = 417) from Northern Japan

    Calcified tissue international

Knee osteophyte development

no changein humans1

1 study
  1. Romosozumab showed no clear effect on knee osteophyte development in humans (versus denosumab).

    “Similarly, no significant differences in knee osteophyte area were found between the groups at either time point.”

    Human trialversus denosumab12 monthsfemalesn = 112

    A randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis

    Scientific reports

Radiographic Union Scale for Hip

no changein humans1

1 study
  1. Romosozumab showed no clear effect on Radiographic Union Scale for Hip in humans (hip fracture surgery).

    “The RUSH scores improved over time across treatment groups but did not differ significantly between the romosozumab and placebo groups.”

    Human trialhip fracture surgeryhip70, 140, or 210 mgn = 332

    A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures

    The Journal of bone and joint surgery. American volume

More on Radiographic Union Scale for Hip

Time to radiographic fracture healing

no changein humans1

1 study
  1. Romosozumab showed no clear effect on time to radiographic fracture healing in humans (hip fracture surgery) (16.4 to 16.9 weeks across treatment groups).

    “The median time to radiographic evidence of healing was 16.4 to 16.9 weeks across treatment groups.”

    Human trialhip fracture surgeryhip70, 140, or 210 mgn = 332

    A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures

    The Journal of bone and joint surgery. American volume

Timed Up and Go test

no changein humans1

1 study
  1. Romosozumab showed no clear effect on timed Up and Go test in humans (open reduction and internal fixation of intertrochanteric or femoral neck hip fractures) (p = 0.198).

    “they did not differ significantly between the romosozumab and placebo groups over weeks 6 to 20 (p = 0.198)”

    Human trialopen reduction and internal fixation of intertrochanteric or femoral neck hip fractures70, 140, or 210 mgweeks 6 to 20n = 332

    A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures

    The Journal of bone and joint surgery. American volume

All 34

What is romosozumab linked with?

16

Studies link romosozumab with 16 measures, most often bone fracture (3 studies), heart failure (2) and major adverse cardiovascular events (2).

Bone fracture

downin humans3

3 studies
  1. Romosozumab lowers the risk of bone fracture in humans.

    “Romosozumab is a monoclonal antibody directed at sclerostin. It has both anabolic and antiresorptive effects and shows broad antifracture efficacy.”

    Reviewfemales

    Management of postmenopausal osteoporosis

    Endocrine reviews

  2. Romosozumab lowers the risk of bone fracture in humans (osteoporosis).

    “Romosozumab significantly improves BMD and reduces fracture risk in postmenopausal women and men with osteoporosis.”

    Reviewosteoporosispostmenopausal women and mens

    Sclerostin and Cardiovascular Risk: Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment

    Biomedicines

  3. Romosozumab lowers the risk of bone fracture in humans (Postmenopausal women at high fracture risk; compared with alendronate).

    “reduces fracture risk more rapidly and more effectively than alendronate, with persisting effects for at least two years after transition to antiresorptive agents.”

    ReviewPostmenopausal women at high fracture risk; compared with alendronatebonefemales

    Romosozumab for the treatment of postmenopausal women at high risk of fracture

    Expert opinion on biological therapy

More on Bone fracture

Heart failure

downin humans2RR 0.438

2 studies
  1. Romosozumab is linked with a lower risk of heart failure in humans (compared with teriparatide/abaloparatide in osteoporosis).

    “Romosozumab participants continued to demonstrate a significantly lower hazard (and improved survival probabilities) of myocardial infarction, heart failure, and death”

    Humanscompared with teriparatide/abaloparatide in osteoporosis1 year

    Cardiovascular Outcomes Following Therapeutic Sclerostin Inhibition Compared With Alternative Anabolic Therapies: A Real-World Propensity Score-Matched Analysis

    Journal of osteoporosis

  2. Romosozumab is linked with a lower risk of heart failure in humans (chronic kidney disease) (2.7% vs. 6.1%; RR, 0.438 [95% CI, 0.292-0.659]).

    “heart failure (2.7% vs. 6.1%; RR, 0.438 [95% CI, 0.292-0.659])”

    Humanschronic kidney disease1095 days94.9% and 93.8% womens

    Cardiovascular Outcomes Associated with Romosozumab Versus Denosumab in Chronic Kidney Disease

    Medicina (Kaunas, Lithuania)

More on Heart failure

Major adverse cardiovascular events

downin humans1upin humans1HR 0.624

2 studies
  1. Romosozumab is linked with a lower risk of major adverse cardiovascular events in humans (compared with teriparatide/abaloparatide in osteoporosis) (HR 0.624, 95% CI 0.567-0.688).

    “We observed a significant association with lower hazard ratios among four- (HR 0.441, 95% CI 0.0.376-0.638, p < 0.0001) and three-point major adverse cardiovascular events (HR 0.624, 95% CI 0.567-0.688, p < 0.0001)”

    Humanscompared with teriparatide/abaloparatide in osteoporosis1 year

    Cardiovascular Outcomes Following Therapeutic Sclerostin Inhibition Compared With Alternative Anabolic Therapies: A Real-World Propensity Score-Matched Analysis

    Journal of osteoporosis

  2. Romosozumab raises the risk of major adverse cardiovascular events in humans (particularly in patients with pre-existing cardiovascular conditions).

    “However, clinical trials report an increased incidence of major adverse cardiovascular events (MACE), particularly in patients with pre-existing cardiovascular conditions”

    Reviewparticularly in patients with pre-existing cardiovascular conditions

    Sclerostin and Cardiovascular Risk: Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment

    Biomedicines

More on Major adverse cardiovascular events

Cardiovascular disease

downin humans2HR 0.645

2 studies
  1. Romosozumab is linked with a lower risk of cardiovascular disease in humans (without a prior cardiovascular history) (HR 0.645, 95% CI 0.438-0.950).

    “romosozumab was associated with significantly lower risks of 3P-MACE at 3-year (hazard ratio (HR) 0.645, 95% confidence interval (CI) 0.438-0.950, p = 0.023)”

    Humanswithout a prior cardiovascular history3 years

    Romosozumab linked to lower risk without prior cardiovascular disease

    Therapeutic advances in musculoskeletal disease

  2. Romosozumab is linked with a lower risk of cardiovascular disease in humans (chronic kidney disease) (12.6% vs. 18.8%; RR, 0.668 [95% CI, 0.553-0.808]).

    “Romosozumab was associated with lower 1095-day cumulative risk of the composite cardiovascular outcome than denosumab (12.6% vs. 18.8%; RR, 0.668 [95% CI, 0.553-0.808])”

    Humanschronic kidney disease1095 days94.9% and 93.8% womens

    Cardiovascular Outcomes Associated with Romosozumab Versus Denosumab in Chronic Kidney Disease

    Medicina (Kaunas, Lithuania)

More on Cardiovascular disease

Bone mineral density

upin humans1

1 study
  1. Romosozumab is associated with bone mineral density in humans (Postmenopausal woman with MONA syndrome and severe osteoporosis).

    “Romosozumab was associated with a substantial increase in BMD and stabilization of vertebral deformities, with no new fractures observed.”

    HumansPostmenopausal woman with MONA syndrome and severe osteoporosisbonefemales

    Significant bone mineral density improvement following sequential Romosozumab-Denosumab therapy in a postmenopausal woman with Multicentric Osteolysis, Nodulosis, and Arthropathy (MONA) syndrome

    Frontiers in endocrinology

More on Bone mineral density

Myocardial infarction

downin humans1

1 study
  1. Romosozumab is linked with a lower risk of myocardial infarction in humans (compared with teriparatide/abaloparatide in osteoporosis).

    “Romosozumab participants continued to demonstrate a significantly lower hazard (and improved survival probabilities) of myocardial infarction, heart failure, and death”

    Humanscompared with teriparatide/abaloparatide in osteoporosis1 year

    Cardiovascular Outcomes Following Therapeutic Sclerostin Inhibition Compared With Alternative Anabolic Therapies: A Real-World Propensity Score-Matched Analysis

    Journal of osteoporosis

More on Myocardial infarction

Chronic ischemic heart disease

upin humans1

1 study
  1. Romosozumab is linked with a higher risk of chronic ischemic heart disease in humans with a prior cardiovascular history.

    “romosozumab was associated with significantly higher risks of 4P-MACE, 5P-MACE, stroke, mortality, and chronic ischemic heart disease across all three follow-up time horizons.”

    Humanswith a prior cardiovascular history

    Romosozumab linked to lower risk without prior cardiovascular disease

    Therapeutic advances in musculoskeletal disease

More on Chronic ischemic heart disease

Stroke

upin humans1

1 study
  1. Romosozumab is linked with a higher risk of stroke in humans with a prior cardiovascular history.

    “among patients with a prior cardiovascular history, romosozumab was associated with significantly higher risks of 4P-MACE, 5P-MACE, stroke, mortality, and chronic ischemic heart disease”

    Humanswith a prior cardiovascular history

    Romosozumab linked to lower risk without prior cardiovascular disease

    Therapeutic advances in musculoskeletal disease

More on Stroke

Alzheimer's disease

downin humans1RR 0.77

1 study
  1. Romosozumab is linked with a lower risk of Alzheimer's disease in humans (compared with teriparatide initiation, 1-year per-protocol analysis) (RR 0.77 (95% CI, 0.65 to 0.86)).

    “For Alzheimer's disease specifically, the ARR was 0.6% (95% confidence interval, 0.3 to 0.9%), with an RR of 0.77 (95% confidence interval, 0.65 to 0.86).”

    Humanscompared with teriparatide initiation, 1-year per-protocol analysis1-year

    Romosozumab versus teriparatide for risk of dementia in individuals with osteoporosis: a target trial emulation study

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

More on Alzheimer's disease

Dementia

downin humans1RR 0.76

1 study
  1. Romosozumab is linked with a lower risk of dementia in humans (compared with teriparatide initiation, 1-year per-protocol analysis) (RR 0.76 (95% CI, 0.69 to 0.82)).

    “In the 1-year per-protocol analyses, the ARR was 1.0% (95% confidence interval, 0.7 to 1.4%), with a RR of 0.76 (95% confidence interval, 0.69 to 0.82).”

    Humanscompared with teriparatide initiation, 1-year per-protocol analysis1-year

    Romosozumab versus teriparatide for risk of dementia in individuals with osteoporosis: a target trial emulation study

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

More on Dementia

All 16

Has romosozumab been tested in people?

0 of 35 about aging

Yes: 4 trials and 18 observational studies in people have been published, and 33 trials are registered.

Approved

  • FDA Evenity

    Apr 9, 2019Osteoporosis, Osteoporosis in Postmenopausal Women

  • EMA Evenity

    Dec 9, 2019Osteoporosis, Osteoporosis in Postmenopausal Women, severe osteoporosis

Repurposing

All 14

In trials

  • FHA

    Phase 3Recruiting1 trial

  • Fracture healing

    Phase 2Results posted1 trial

Who is developing romosozumab?

2 companies: Amgen and UCB Biopharma SRL.

Companies
  • AmgenPhase 4postmenopausal osteoporosis, osteogenesis imperfecta
  • UCB Biopharma SRLPhase 3osteoporosis

Trial sponsors

Funding

1 grant since 2020

Japan Society for the Promotion of Science¥4.2M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    In humans with osteoporosis, romosozumab increases lumbar spine and alveolar bone mineral density. A human study also reports reduced TRACP-5b and P1NP levels following monthly subcutaneous treatment.

  2. Summary written from the findings.

Latest

Dec 2025: 2Jan 2026: 1Feb 2026: 4Mar 2026: 2Apr 2026: 4May 2026: 2Jun 2026: 1Jul 2026: 7Aug 2026: 1Sep 2026: 7Oct 2026: 3Nov 2026: 539 papers in 12 months
Diabetes & Metabolism

Diabetes risk did not clearly differ between osteoporosis drugs

The hazard ratio for type 2 diabetes, comparing risk over time, was 0.93 for romosozumab versus denosumab, with no statistically clear difference.The hazard ratio for type 2 diabetes, comparing risk over time, was 0.93 for romosozumab versus denosumab, with no statistically clear difference.

See all 70 papers on romosozumab